Overview

This is a summary of the European public assessment report (EPAR) for Memantine LEK. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Memantine LEK.

For practical information about using Memantine LEK, patients should read the package leaflet or contact their doctor or pharmacist.

Memantine LEK is a medicine used to treat patients with moderate to severe Alzheimer’s disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour. It contains the active substance memantine.

Memantine LEK is a ‘generic medicine’. This means that Memantine LEK is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Ebixa.

Memantine LEK is available as 10-mg and 20-mg tablets and can only be obtained with a prescription.

Treatment should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease. Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine LEK by the patient.

Memantine LEK should be given once a day at the same time every day. To prevent side effects, the dose of Memantine LEK is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day. The tolerance and dose should be assessed within three months after starting treatment, and from then on the benefits of continuing treatment with Memantine LEK should be reassessed on a regular basis. The dose may need to be reduced in patients who have moderate or severe problems with their kidneys.

For more information, see the package leaflet.

The active substance in Memantine LEK, memantine, is an antidementia medicine. The cause of Alzheimer’s disease is unknown, but memory loss in the disease is believed to be due to a disturbance of message signals in the brain.

Memantine works by blocking special types of receptor called N-methyl-D-aspartate (NMDA) receptors, to which the neurotransmitter glutamate normally attaches. Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another. Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer’s disease. In addition, overstimulation of the NMDA receptors may result in cell damage or death. By blocking NMDA receptors, memantine improves the transmission of signals in the brain and reduces the symptoms of Alzheimer’s disease.

Because Memantine LEK is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Axura. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

Because Memantine LEK is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Memantine LEK has been shown to have comparable quality and to be bioequivalent to Axura. Therefore, the CHMP’s view was that, as for Axura, the benefit outweighs the identified risk. The Committee recommended that Memantine LEK be approved for use in the EU.

Safety information has been included in the summary of product characteristics and the package leaflet for Memantine LEK, including the appropriate precautions to be followed by healthcare professionals and patients.

The European Commission granted a marketing authorisation valid throughout the European Union for Memantine LEK on 22 April 2013.

For more information about treatment with Memantine LEK, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Memantine LEK : EPAR - Summary for the public

български (BG) (130.21 KB - PDF)
español (ES) (99.66 KB - PDF)
čeština (CS) (122.78 KB - PDF)
dansk (DA) (96.59 KB - PDF)
Deutsch (DE) (76.02 KB - PDF)
eesti keel (ET) (75.8 KB - PDF)
ελληνικά (EL) (101.3 KB - PDF)
français (FR) (97.86 KB - PDF)
italiano (IT) (97.32 KB - PDF)
latviešu valoda (LV) (96.92 KB - PDF)
lietuvių kalba (LT) (122.35 KB - PDF)
magyar (HU) (97.5 KB - PDF)
Malti (MT) (124.6 KB - PDF)
Nederlands (NL) (99.77 KB - PDF)
polski (PL) (100.52 KB - PDF)
português (PT) (97.57 KB - PDF)
română (RO) (97.28 KB - PDF)
slovenčina (SK) (122.46 KB - PDF)
slovenščina (SL) (117.4 KB - PDF)
Suomi (FI) (98.62 KB - PDF)
svenska (SV) (96.96 KB - PDF)

Product information

Memantine LEK : EPAR - Product Information

български (BG) (463.1 KB - PDF)
español (ES) (417.5 KB - PDF)
čeština (CS) (457.72 KB - PDF)
dansk (DA) (419.44 KB - PDF)
Deutsch (DE) (428.75 KB - PDF)
eesti keel (ET) (401.01 KB - PDF)
ελληνικά (EL) (453.89 KB - PDF)
français (FR) (427.08 KB - PDF)
hrvatski (HR) (418.74 KB - PDF)
íslenska (IS) (413.96 KB - PDF)
italiano (IT) (414.17 KB - PDF)
latviešu valoda (LV) (442.56 KB - PDF)
lietuvių kalba (LT) (415.13 KB - PDF)
magyar (HU) (423.02 KB - PDF)
Malti (MT) (450.35 KB - PDF)
Nederlands (NL) (453.15 KB - PDF)
norsk (NO) (404.23 KB - PDF)
polski (PL) (419.26 KB - PDF)
português (PT) (408.14 KB - PDF)
română (RO) (448.7 KB - PDF)
slovenčina (SK) (441.83 KB - PDF)
slovenščina (SL) (407.95 KB - PDF)
Suomi (FI) (405.36 KB - PDF)
svenska (SV) (404.05 KB - PDF)

Latest procedure affecting product information: IB/0010

20/10/2020

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Memantine LEK : EPAR - All Authorised presentations

български (BG) (45.59 KB - PDF)
español (ES) (15.59 KB - PDF)
čeština (CS) (27.82 KB - PDF)
dansk (DA) (14.08 KB - PDF)
Deutsch (DE) (11.67 KB - PDF)
eesti keel (ET) (15.16 KB - PDF)
ελληνικά (EL) (47.29 KB - PDF)
français (FR) (14.27 KB - PDF)
hrvatski (HR) (37.13 KB - PDF)
íslenska (IS) (12.4 KB - PDF)
italiano (IT) (14.14 KB - PDF)
latviešu valoda (LV) (43.84 KB - PDF)
lietuvių kalba (LT) (44.28 KB - PDF)
magyar (HU) (43.28 KB - PDF)
Malti (MT) (43.14 KB - PDF)
Nederlands (NL) (14.11 KB - PDF)
norsk (NO) (11.62 KB - PDF)
polski (PL) (25.39 KB - PDF)
português (PT) (15.37 KB - PDF)
română (RO) (42.5 KB - PDF)
slovenčina (SK) (27.58 KB - PDF)
slovenščina (SL) (27.13 KB - PDF)
Suomi (FI) (14.07 KB - PDF)
svenska (SV) (14.16 KB - PDF)

Product details

Name of medicine
Memantine LEK
Active substance
memantine hydrochloride
International non-proprietary name (INN) or common name
memantine
Therapeutic area (MeSH)
Alzheimer Disease
Anatomical therapeutic chemical (ATC) code
N06DX01

Pharmacotherapeutic group

  • Psychoanaleptics
  • Other anti-dementia drugs

Therapeutic indication

Treatment of patients with moderate to severe Alzheimer’s disease.

Authorisation details

EMA product number
EMEA/H/C/002630

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Pharmathen S.A.

6, Dervenakion str.
15351 Pallini
Attiki
Greece

Marketing authorisation issued
21/04/2013
Revision
5

Assessment history

Memantine LEK : EPAR - Procedural steps taken and scientific information after authorisation

Memantine LEK : EPAR - Public assessment report

CHMP summary of positive opinion for Memantine LEK

This page was last updated on

How useful do you find this page?